FUNDED PROJECTS

We are developing several strategic projects to improve the production of biosimilars

GH Genhelix is implementing its Strategic Plan to enhance the production of monoclonal antibodies, as part of our strong commitment to research, development, and innovation in biosimilar medicines.

This plan is partially funded by the Business Competitiveness Institute of the Regional Government of Castilla y León (ICECYL), with financial support from the European Union, through the European Regional Development Fund (FEDER). The objective is to boost research, technological development, and innovation.

Implementation period: July 2024 – July 2027

PROJECT
PROJECT: DEVELOPMENT OF A FORMULATION BASED ON A MONOCLONAL ANTIBODY FOR THE FUTURE DEVELOPMENT OF A BIOSIMILAR CANDIDATE

File No.: 10/23/LE/0006

PROJECT
PROJECT: PRODUCTION OF A MONOCLONAL ANTIBODY BIOSIMILAR FOR CANCER TREATMENT

File No.: 10/23/LE/0007

PROJECT
PROJECT: DEVELOPMENT OF A PREDICTIVE ARTIFICIAL INTELLIGENCE MODEL INTEGRATED INTO A DIGITAL TWIN

File No.: 10/23/LE/0008